NCT01502137 - Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Chronic Kidney DiseaseEnd-Stage Renal DiseaseHealthy

Interventions

DRUG

somatropin

Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.

DRUG

somatropin

Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.

Trial Locations (1)

81241

Novo Nordisk Investigational Site, München